{"disease":{"id":"communication-disabilities","name":"communication disabilities"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04697212","title":"Improving Communication and Healthcare Outcomes for Patients With Communication Disabilities","phase":"NA","overall_status":"COMPLETED","enrollment_count":687,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT03276559","title":"Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07278544","title":"Harnessing Communication Preferences","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Joel E. Ringdahl","has_results":false},{"nct_id":"NCT05808478","title":"Eye-tracking Technology for Severe Communication Disability","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"IRCCS Centro Neurolesi Bonino Pulejo","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}